Latisse™ is the only FDA approved eyelash product to grow lashes longer, fuller and darker!
The first and only prescription treatment approved by the FDA for inadequate or insufficient eyelashes, growing them longer, fuller and darker.
Great eyelashes don’t just happen overnight. That’s why it’s important to note that Latisse™ (bimatoprost ophthalmic solution 0.03%) works gradually and remarkably—starting at 4 weeks with full results after 16 weeks. Once you begin treatment, you could start to see results in as little as 4 weeks, but you must continue applying the topical treatment each night and follow the directions for best results. Remember, results are gradual over time.
Your eyelashes will experience real measurable growth.
Latisse™ works from the inside out. As the treatment progresses, you’ll begin to see changes in length, thickness, and darkness gradually. After week 16, you’ll see the full effect of Latisse™—and so will others.
There are possible side effects.
Throughout clinical trials, some users did experience itchy eyes and eye redness. However, some users found that these irritations went away once they became accustomed to the product or began applying it properly. As with any prescription treatment, always consult with your doctor for information and proper usage of Latisse™ solution.
In the clinical study, 78% saw significant increases in length, fullness, and darkness at week 16. For more information, visit http://www.latisse.com.
Important Safety Information
Latisse™ is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.
Bimatoprost ophthalmic solution (LUMIGAN®) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, Latisse™ lowered IOP, however, the magnitude of the reduction was not cause for clinical concern. In ocular hypertension studies with LUMIGAN®, it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of Latisse™ may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE™ after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with Latisse™, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.